Mathieu Desclaux

Title: The Innovative Contributions of Mathieu Desclaux

Introduction

Mathieu Desclaux is a notable inventor based in Brooklyn, NY (US). He has made significant contributions to the field of tauopathy research, holding a total of 3 patents. His work focuses on understanding the genetic factors that influence tau aggregation, which is crucial for developing therapeutic strategies for tauopathies.

Latest Patents

Desclaux's latest patents include innovative models of tauopathy that identify the genes BANF1, PPP2CA, and ANKLE2 as key players in promoting tau aggregation when disrupted. These improved tauopathy models encompass cells, tissues, or animals that exhibit mutations or inhibited expression of these genes. Furthermore, his patents outline methods for utilizing these models to assess therapeutic candidates aimed at treating tauopathies. They also detail techniques for creating these improved models and methods for accelerating or exacerbating tau aggregation in a tauopathy model.

Career Highlights

Mathieu Desclaux is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to advance his research in tauopathy. His work is pivotal in the ongoing quest to understand and treat neurodegenerative diseases associated with tau aggregation.

Collaborations

Desclaux collaborates with talented colleagues, including Marine Prissette and Matthew Koss, who contribute to the innovative research environment at Regeneron Pharmaceuticals.

Conclusion

Mathieu Desclaux's contributions to tauopathy research and his innovative patents highlight his role as a leading inventor in the field. His work not only enhances our understanding of tau aggregation but also paves the way for potential therapeutic advancements.